Asparaginase use for the treatment of acute lymphoblastic leukemia

Barba, Pere; Dapena, José Luís; Montesinos, Pau; Rives, Susana

doi:10.1016/j.medcle.2017.03.002

Cited by 6 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several factors can contribute to this difference, including low socioeconomic status, scarcity of some antineoplastic agents or lower investment in supportive care, such as monitoring the quality and activity of drugs such as asparaginase (ASNase). Today it is evident that the such monitoring leads to a better treatment result since it allows practitioners to assess enzymatic activity during therapy and incorporate these data into treatment management decisions 5‐11 . ASNase preparations could have different half‐lives and different initial concentrations, probably because of distinct E. coli strains 12 .…”

Section: Introductionmentioning

confidence: 99%

Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study

et al. 2021

View full text Add to dashboard Cite

Summary Our group recently showed that the (ASNase) formulation available in Brazil from 2017 to 2018 when used at the same dose and frequency as the formulation provided previously did not reach the activity considered therapeutic. Based on these, our goal was to assess the impact of these facts on the prognosis of children with ALL at different oncology centers. A multicentre retrospective observational study followed by a prospective follow‐up. Patients aged >1 and <18 years in first‐line treatment followed up at 10 referral centres, between 2014 and 2018 who received the formulation Leuginase® were identified (Group B). For each patient, the centre registered 2 patients who received ASNase in the presentation of Aginasa® exclusively (Group A). Data collection was registered using (Redcap®). A total of 419 patients were included; 282 in Group A and 137 in B. Group A had a 3‐year OS and EFS of 91·8% and 84·8% respectively, while Group B had a 3‐year OS of 83·8% (P = 0·003) and EFS of 76·1% (P = 0·008). There was an impact on 3‐year OS and EFS of children who received a formulation. This result highlights the importance of evaluating ASNase and monitoring its activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 7 , 8 Three main types of ASNase have been used so far: native ASNase derived from Escherichia coli , an enzyme isolated from Erwinia chrysanthemi, referred to as Erwinia ASNase and a pegylated form of the native E. coli ASNase. 2 , 9 , 10 The enzyme derived from E. coli is indicated in most first-line therapy, while the Erwinia -derived ASNase is reserved for patients who develop hypersensitivity reactions to the previous form. 10 , 11 , 12 …”

Section: Introductionmentioning

confidence: 99%

“… 16 , 17 Other side effects are hypoalbuminemia, anaphylaxis, pancreatitis, hyperglycemia, hyperlipidemia, urticaria, bronchospasm, angioedema and coagulation abnormalities that may lead to intracranial thrombosis or hemorrhage. 9 , 10 …”

Section: Introductionmentioning

confidence: 99%

Asparaginase: an old drug with new questions

Cecconello

Magalhães

Werlang

et al. 2020

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

The long-term outcome of acute lymphoblastic leukemia has improved dramatically due to the development of more effective treatment strategies. L-asparaginase (ASNase) is one of the main drugs used and causes death of leukemic cells by systematically depleting the non-essential amino acid asparagine. Three main types of ASNase have been used so far: native ASNase derived from Escherichia coli , an enzyme isolated from Erwinia chrysanthemi and a pegylated form of the native E. coli ASNase, the ASNase PEG. Hypersensitivity reactions are the main complication related to this drug. Although clinical allergies may be important, a major concern is that antibodies produced in response to ASNase may cause rapid inactivation of ASNase, leading to a worse prognosis. This reaction is commonly referred to as "silent hypersensitivity" or "silent inactivation". We are able to analyze hypersensitivity and inactivation processes by the measurement of the ASNase activity. The ability to individualize the ASNase therapy in patients, adjusting the dose or switching patients with silent inactivation to an alternate ASNase preparation may help improve outcomes in those patients. This review article aims to describe the pathophysiology of the inactivation process, how to diagnose it and finally how to manage it.

show abstract

“…Due of its efficacy in selective killing of leukemic cells, it is also considered as a targeted therapy (Rizzari, 2013). But since the drug in present use bears many side effects (Barba, 2017;Shrivastava, 2016), researchers are in continuous search of new sources for this enzyme. The non-immunological side effects of this enzyme can be mitigated by the discovery of new sources for L-Asparaginase enzyme and its characterization (Ali, 2016).…”

Section: Introductionmentioning

confidence: 99%

Isolation Screening and Identification of Bacterial Endophytes from Medicinal Plants as a potential source of L-Asparaginase Enzyme

Abhini¹,

K²

2018

JCHPS

View full text Add to dashboard Cite

L-Asparaginase is an enzyme (EC3.5.1.1) used as chemotherapeutic agent for the treatment of Acute Lymphoblastic Leukemia (ALL). The commercial L-Asparaginase now available is of bacterial origin and since it shows many side effects, search for alternative sources of this enzyme is highly necessary, owing to its high therapeutic significance. In the present study an attempt has been made to isolate bacterial endophytes, with L-Asparaginase potentiality, from medicinal plants. From 16 different medicinal plants 127 bacterial endophytes have been isolated, among which 51 endophytes were capable of producing L-Asparaginase enzyme. Two isolates that showed excellent enzyme activity as 1.436 U/ml and 1.827 U/ml were identified, based on biochemical tests and 16s rRNA gene sequencing, as Acinetobacter baumannii and Bacillus subtilis which were isolated from the medicinal plants, Annona muricata and Averrhoa carambola respectively. The phylogenetic tree for the two isolates were constructed based on the 16s rRNA blast results and the 16s rRNA gene sequences were deposited in gene bank and accession numbers were received.

show abstract

Asparaginase use for the treatment of acute lymphoblastic leukemia

Cited by 6 publications

References 30 publications

Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study

Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study

Asparaginase: an old drug with new questions

Isolation Screening and Identification of Bacterial Endophytes from Medicinal Plants as a potential source of L-Asparaginase Enzyme

Contact Info

Product

Resources

About